SCHEMBL1638166

SCHEMBL1638166

Cc1ccc(C(=O)CC(=NNC(=O)c2ccccc2O)C(F)(F)F)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.53
LMNA P02545 7/20 0.53
HTT P42858 4/20 0.53
GAA P10253 8/20 0.49
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
SMN1; SMN2 Q16637 7/20 0.48
NPC1 O15118 5/20 0.48
RAB9A P51151 4/20 0.48
HPGD P15428 4/20 0.48
KDM4E B2RXH2 5/20 0.45
ALDH1A1 P00352 3/20 0.45
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.42
THRB P10828 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1638164 1.00 MAPT (0.53) MAPTLMNAHTTGAAMEN1
SCHEMBL1637236 0.88 MAPT (0.54) MAPTLMNAHTTGAAMEN1
SCHEMBL1637237 0.88 MAPT (0.54) MAPTLMNAHTTGAAMEN1
SCHEMBL1638791 0.82 MAPT (0.78) MAPTLMNAHTTGAAMEN1
SCHEMBL1638795 0.82 MAPT (0.78) MAPTLMNAHTTGAAMEN1
SCHEMBL1637443 0.81 MAPT (0.52) MAPTLMNAHTTGAAMEN1
SCHEMBL1638632 0.81 MAPT (0.52) MAPTLMNAHTTGAAMEN1
SCHEMBL1638330 0.77 GAA (0.51) MAPTLMNAHTTGAAMEN1
SCHEMBL1638328 0.77 GAA (0.51) MAPTLMNAHTTGAAMEN1
SCHEMBL12726682 0.76 KDM4E (0.53) MAPTLMNAHTTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 MAPT 85/4885LMNA 2595/4885HTT 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.